Best overall response
| Best response* . | TN ≥65 y (n = 31) . | R/R (n = 101) . | R/R del(17p) (n = 34) . | All patients (N = 132) . |
|---|---|---|---|---|
| ORR (CR+PR+PR-L) | 26 (84) | 91 (90) | 27 (79) | 117 (89) |
| CR | 7 (23) | 7 (7) | 2 (6) | 14 (11) |
| PR | 17 (55) | 81 (80) | 22 (65) | 98 (74) |
| PR-L | 2 (6) | 3 (3) | 3 (9) | 5 (4) |
| SD | 3 (10) | 4 (4) | 4 (12) | 7 (5) |
| PD | 0 | 2 (2) | 1 (3) | 2 (2) |
| Missing | 2 (6) | 4 (4) | 2 (6) | 6 (5) |
| Best response* . | TN ≥65 y (n = 31) . | R/R (n = 101) . | R/R del(17p) (n = 34) . | All patients (N = 132) . |
|---|---|---|---|---|
| ORR (CR+PR+PR-L) | 26 (84) | 91 (90) | 27 (79) | 117 (89) |
| CR | 7 (23) | 7 (7) | 2 (6) | 14 (11) |
| PR | 17 (55) | 81 (80) | 22 (65) | 98 (74) |
| PR-L | 2 (6) | 3 (3) | 3 (9) | 5 (4) |
| SD | 3 (10) | 4 (4) | 4 (12) | 7 (5) |
| PD | 0 | 2 (2) | 1 (3) | 2 (2) |
| Missing | 2 (6) | 4 (4) | 2 (6) | 6 (5) |
Values are n (%).
By investigator assessment. NE, not evaluable; PD, progressive disease; SD, stable disease.